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group,arterialocclusionwas determinedmacroscopicellyaftersacrifice.
f?esukare showninthe table.Comparedwithcontrolvessels(Gr. 11),ar-
terieswithconjugate-immobilisedstents(Gr. 1)hadsignificantlyIessaplatelet
deposition(P= 0.0003), fewer episodesof bCFV (P= 0.0011), highermean
C2-hourflow (P = 0.0002) and significantlyhigherarterialpatency‘rates (P
= 0.027).
Corrc/usion:Platelet-tSrgetSdurokinaeepassivelyimmobilisedtopolymer-
coetedstentemarkedlyreducestheirthrombogenicity.Suchdevicesmaybe
particularlyuaefulforanticoagulant-freestentinginsmallvessela. orforbailout
stentingand meritfurtherevaluation.
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n7715 A New Biodegradable Polylectic Acid CoronaryStent-Coating, Releasing PEG-Hirudin and a
Prostacycline Analog, Reduces Both Platelet
Activation and Plasmatic Coagulation
G.Schmidmaier, A. Stemberger1, E. Alt, M. Gawaz, F.-J.Neumann,
A. Sch6mig.1.Med. Klinik, Inst. for Exp. Surgery Germany 1 Tahnische
Universit.4tMOnchen,Germany
Experiencewithcoronarystentinghasdemonstratadthatadhesionofplasma
proteinsto the metallicstentsurfaceand plateletactivationlimitthe implant
effeotivenesaby meansof acuteand subacutethrombosis.We investigated
a new stentcoatingof polylacticacid (PLA) carrier(25 kDa) containing5%
polyethyleneglycol-hirudinand 1% prostacyclinanalog(PG12).Methods:7
mm metallicatents (n = 46) were tested coated vs uncoatedin a human
atasis model with the non-anticoagulatacfblood of healthy volunteers. After
5 min thrombusweight,aPTT, markersof”acfivatedcoagulation(thrombin-
antithrombin-complexesTAT 01and prothmmbinfragmentaF1–2), mllagen
inducedplateletaggregationand CD62p/CD4i expressionwere measured
andscanningelectronmicroacopyperformed.Ffesults:Uncoatedstentswere
completelycovered by a coagulationplug rich in fibrinand platelets.The
costed stents were practically free from thrombotic material.
Controlwithoutstent Uncoatedstent Coated etent
Thrombua(mg) 2.02 * 0.50”” 0.02+0.01
aPIT (sac) 29.87 *2.54 29,60 + 2.35** 58.7759.24
TAT 01(pmol/1) 5.92 +0.S4 25.52 A 4.45** 6.03+ 1.13
FI-2 lnmolll) 0.94+0.07 2.14+0.33** 0.99* 6.06
Piat~l~t”Agg~eg. (%) 92.13*4.24 90.62 *4.34*” 10.53* 0.33
AcDs2p 10.0s * 0.66 12.63 + 1.S4” 11.73+ 0.62
CD41a 146.56 + 5.S7 lS2.S3&4.78” 21.43+3.22
*P< 0.05,**P <0.001, Coatedvs uncOated Stent
Conclusion.’ Our results show that PIA stent coating releasing PEG-
hirudinandaprostacyclinanaloghasa significanteffectonbothplateletacti-
vationand plasmaticcoagulation,therebypreventingstentinducedthrombus
formation.
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m771 6 High-Shear Overridea the Antithrombotic Effects of
Aspirin on Stent Thrombosis
R. Makkar,F. Litvack,S. Kaul,H. Zeng, N. Eigler.Cedars-Sinai Medical
Center, Los Angeles, CA, USA
Shear at stent surfacea is affected by vessel size, blood flow, pre-existing
thrombusand adSCfuaCYofstentdeployment. Wetestedthe effiCSCYofaSPirin
(10 or 20 mg/kg iv) at different blood shear rates. Unpolished nitinol stents
(n= 46) were expanded to a diameter of 2 mm in a perfuaion chamber and
exposed to flowing arterial blood (n = 6 pigs) for 20 minutes in a porcine
arteriovenous shunt model of stent thrombosis. Shear was regulated by
altering the blood flow. Stent thrombosis was quantified by measuring dry
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thrombus weight. Data are mean + sd. Arachidonic acid (540 mM)-induced
Dlatelet aggregation was inhibited by 48 +5% (P < 0.01) and bleedin9 time
was mild~-pr;longed (360 * 50 vs. 200 + 30”secs; p = ns) with ASA 10
mg/kg. Higher doses of aspirin (20 mg/kg) simiiarly failed to inhibit ST (17 +
2 vs 19+ 1 mg for control, n =6; p = ns) at the highest shear.
Conclusion: ASA inhibits stent thrombosis at low but not at high shear
rates. In high-risk clinical situations characterized by high blood shear, ASA
alone may not provide sufficient antiplatelet activity.
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1772-1I predictor~ofsuccesaand~~jor~omPl,~ationsfor
Primary PTCA in Acute Myocardial Infarction
E.D. Grassman, S.A. Johnson, R.J. Krone. Loyo/a University Medical
Centec Maywood, IL, USA, Washington UniveraiV, St. Louis, MO, USA
Primaryangioplastyhas recentlybeen advocatedas a safe and moreeffec-
tivetreatmentthanthrombolytictherapyforacutemyocardialinfarction(AMI).
The Socieiy for Cardiac Angiography and Interventions (SCA&l) maintains
a regist~ for diagnostic and intetventional procedures. Primary angioplasty
for AMI in the laboratories contributing to the registw was reviewed, and
predictors of successful PTCA, in-hospital mortality, and emergency CABG
were identified. 4,366 PTCA procedures were performed for AMI without
prior thrombolytic therapy among 78,199 PTCA’S (5.6%). Lab volume, age,
sex, symptoms, intreaotiic balloon pump (IABP) use, prior AMI, prior CABG,
diabetes, hypertension, shock, moribund state, CHF, and prior PTCA of the
same aitewereanalyzed. The overall success rate was 91.5%, the in-hospital
morkelifyrate was 2.5%, and the rate of emergency CABG was 3.&’o. These
are all similar to other published series. Higher PTCA volume and lower age
wera predictive of successful PTCA using multivariable logistic regression
analysis, while an IABP in place, shock, and moribund state had negative
predictive effects (p< 0.05). Unsuccessful PTCA, shock, and moribund state
were predictive of in-hospital death (p < 0.05). Unsuccessful PTCA, the ab-
sence of hypertension,and absence of CHF were predictiveof emergency
CABG (p < 0.05).
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1772-21Nine-yearoutcomeofpatiente”nder~oin9
Percutaneous Transluminal Coronary Angioplaety
for Acute Myocardial Infarction: Repo~ from the
1985-1986 NHLBI PTCA Regiatry
S.T. Lee, D.O. Williams, C.R. Cannan, K.E. Kip, S.F. Kelsey, K.M. Detre.
Rhode /s/and Hospital, Brown University Providence, RI, USA
Percutaneoustransluminal coronatyangioplasty (PTCA)isan effeofivemeans
of achieving reperfusion in patients with acute myocardial infarction, but the
long-term outcome of this therapy is unknown. Accordingly, we foilowed the
clinical status of 1320 consecutive PTCA patients without history of Ml (no
Ml), 619 patients with Ml >30 days prior to PTCA (remote Ml), 373 patients
with Ml 46 hours to 30 days prior to PTCA (recent Ml), and 119 patients
with Ml within 46 hours of PTCA (acute Ml). The in-hospital mortalities were
no Ml 0.8Y0, remote Ml 1.0%, recent Ml 1.9%, and acute Ml 9.2% (p <
0.001). After a median of 9.0 years of follow-up, the risk of subsequent Ml or
bypass surgery did not differ by pre-procedural Ml,status with the exception
that acute Ml patients had less repeat PTCA (20.9$’.) than the other three
groups (range 31.5%-42.7%, p < 0.01). Crude nine-year mortality, however,
was higheat in the acute Ml patients (41.8Yo)when compared with recent
Ml (22.8%), remote Ml (25.1%), and no Ml patients (17.9%, p c 0.001).
After adjusted multivariate analysis, Ml within 48 hours of PTCA remained an
independent predictor of nine-year mortality (relative risk= 1.75, p c 0.01).
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